Drugmakers flag concerns over blue-strip antibiotic labels

The government mandated a blue line on antibiotic packaging to curb misuse. However, pharmaceutical companies argue this will disrupt operations and finances. They believe the measure lacks scientific backing and global alignment. Industry associations are urging the government to withdraw the notification. Existing regulations already address antimicrobial resistance concerns.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GuhQOfs
via IFTTT

Read More

ChrysCapital, two others launch open offer for Novartis India

A consortium including WaveRise Investments, ChrysCapital, and Two Infinity Partners is set to acquire a significant stake in Novartis India. This move is part of Novartis's strategy to divest its stake. The transaction is expected to conclude in the third quarter of 2026. Novartis will continue its operations in India through Novartis Healthcare.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lQVLZwt
via IFTTT

Read More

Indian drugmaker Sai Life Sciences to boost headcount by about 20% amid global demand upswing

Sai Life Sciences will boost its workforce by over 700 employees next financial year. This expansion supports growing global demand for its services. The company is increasing capacity to meet this demand. New hires will focus on scientific, technical, and management roles. This move reflects a broader trend of global pharma companies expanding in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ExMusJk
via IFTTT

Read More

Thyroid, antibiotic drugs face fresh safety warnings after national review

New safety warnings are coming for two common medicines, doxycycline and carbimazole. Indian drug regulators have identified potential mental health side effects for doxycycline. Carbimazole will now carry stronger warnings about a rare but serious blood disorder. Manufacturers must update prescribing information. These changes aim to improve patient safety by highlighting important risks.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/H09vWqY
via IFTTT

Read More

Zydus launches biosimilar for ophthalmic care

Zydus Lifesciences has introduced Anyra, its first indigenously developed biosimilar for the treatment of visual impairment in India. This innovative drug, akin to Aflibercept 2 mg, addresses vision loss resulting from diseases like diabetes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eCiGEwj
via IFTTT

Read More

Pharma firms asked for side-effects of common medicines

India's drug regulator has issued new safety warnings for common medicines. Doxycycline, an antibiotic, will now list side effects like anxiety and dizziness. Carbimazole, used for thyroid issues, will highlight the risk of a life-threatening condition called agranulocytosis. Manufacturers must update package inserts and promotional materials. These changes follow recommendations from pharmacovigilance experts to ensure patient safety.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QCPknbg
via IFTTT

Read More

Warburg Pincus talks in final lap to buy Integrace Health for Rs 1,200 crore

Integrace is currently owned by homegrown PE fund True North and Singapore sovereign investor Temasek Holdings. True North Fund VI LLP holds a 55.83% stake in Integrace, while Temasek arm V-Science Investments Pte owns 43.91%.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/t7hfmGZ
via IFTTT

Read More

Steroid abuse among gym-goers raises heart, liver risks; issue raised in Parliament

Young people are facing severe health issues due to steroids and unsafe supplements. Doctors report liver toxicity, infertility, and aggression. Heart specialists warn of life-threatening consequences like heart attacks. Mental health experts note links to depression and anxiety. The market for these substances requires stricter checks and greater awareness among youth.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HaBfwyV
via IFTTT

Read More

Seeing with sound: AIIMS distributes AI-powered smart glasses to help visually impaired

AIIMS has equipped 53 visually impaired individuals with advanced AI-powered smart vision glasses, transforming their environments into audible guidance. This innovative project empowers both children and adults to navigate life with newfound independence.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yZ6uDUx
via IFTTT

Read More

AI can address health inequities, but cannot replace human touch: Union MoS Health Anupriya Patel

Speaking at the AI Impact Summit in the national capital, Patel asserted that India's governance model positions AI as an enabler and force multiplier, bringing the country closer to the goals of inclusivity and health equity.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3wjVESA
via IFTTT

Read More

29 vitamin-mineral FDC drugs under review for possible ban over 'irrational' tag

A looming ban on twenty-nine vitamin and mineral combination drugs has sparked a heated debate. Initially flagged as irrational by an expert panel in 2015, these products are now being re-evaluated by a specialized sub-committee. Before any final ruling, the companies will be given a chance to defend their products.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eWhaIyb
via IFTTT

Read More

Lupin signs supply deal to launch antidepressant in Canada

Drug firm Lupin has partnered with Spektus Pharma. They will commercialise the antidepressant DeslaFlex in Canada. This collaboration combines Lupin's Canadian presence with Spektus's formulation expertise. It aims to offer patients more personalized care for Major Depressive Disorder. The deal strengthens Lupin's central nervous system portfolio. Lupin shares saw a slight increase on Monday.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kMS69A4
via IFTTT

Read More

Alkem Labs' Chakan facility gets six observations in USFDA inspection, no data integrity issues

Alkem Laboratories announced its subsidiary Enzene Biosciences received a Form 483 from the USFDA. The inspection at the Chakan manufacturing unit resulted in six procedural observations. The company highlighted zero observations related to data integrity. Enzene is preparing its response to the USFDA within the given timeline. Corrective actions are also being initiated.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uRrOng6
via IFTTT

Read More

Govt looks to provide access to AI resources to medical students: Official

The government plans to give medical students access to e-books and AI tools. This initiative will begin with 57 government medical colleges in smaller towns and rural areas. The aim is to improve students' skills by providing better access to digital and AI-powered learning materials. The program will gradually expand to include private colleges later.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PVv2AMH
via IFTTT

Read More

Adven Biotech says it's India's first homeopathic brand to get NABL certification

Adven Biotech achieves a significant milestone as India's first homeopathy brand to earn NABL certification. This accreditation underscores India's commitment to global healthcare standards in the Ayush sector. The certification validates Adven's quality control and testing laboratories, aligning with Prime Minister Modi's vision for Ayush. It aims to boost confidence and expand the global acceptance of Indian homeopathy.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zTj9iAE
via IFTTT

Read More

GST rejig marks key shift towards making cancer care affordable, AIIMS researchers says

AIIMS researchers highlight recent GST reforms, including tax exemptions on cancer drugs and medical equipment, aiming to make cancer care more affordable. Increased taxation on tobacco products is also noted as a positive step for public health and revenue generation for cancer initiatives.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/g7EB8Ql
via IFTTT

Read More

India becoming backbone of global clinical research

India has emerged as a key player in international clinical trials, showcasing resilience even in the face of global hurdles. With research and innovation on the rise, firms like Parexel recognize India's crucial contribution to ensuring consistent business operations. Instead of threats, artificial intelligence presents avenues for professionals to expand their roles and skillsets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZivtCy1
via IFTTT

Read More

Alkem Labs unit to buy up to 55% of Occlutech for $118 million

Alkem Laboratories is entering the advanced cardiovascular devices market. Its medical devices unit will acquire a significant stake in Switzerland's Occlutech Holding. This strategic move aims to access high-value global markets. The deal is expected to finalize by June 2026. Occlutech is a key player in Europe's minimally invasive cardiac implants.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QRcUVtm
via IFTTT

Read More

AIIMS Delhi first in country to announce launch of face transplant programme

AIIMS New Delhi has become the first hospital in India to introduce face transplantation, a complex reconstructive procedure for patients with severe facial deformities. The Department of Plastic, Reconstructive and Burns Surgery has begun creating a patient registry and is conducting specialised training, including a cadaveric workshop, with support from international expert Dr Indranil Sinha of Harvard Medical School.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zHdnsOB
via IFTTT

Read More

HUL turns ₹70 cr bet in Wellbeing Nutrition into ₹307 cr exit

Hindustan Unilever has divested its 19.8% stake in Wellbeing Nutrition to UVS Pharma for Rs 307 crore. This move comes after HUL's initial Rs 70 crore investment in 2022. The transaction, expected to conclude by March 2026, sees Wellbeing Nutrition valued at approximately Rs 1,600 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/r7hxTCY
via IFTTT

Read More

Zydus settles US Mirabegron patent dispute with Astellas for $120 million

Zydus Lifesciences and its US subsidiary have settled patent litigation with Astellas Pharma over Astellas' Myrbetriq. Zydus will pay Astellas $120 million upfront and a per-unit licensing fee on generic Mirabegron sales until September 2027. This agreement resolves all disputes and allows Zydus to continue marketing its generic version in the US.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/u2lCe6r
via IFTTT

Read More

USV Pharma leads race to buy 85% stake in Wellbeing Nutrition at Rs 1,600 crore valuation

The Mumbai-based brand, owned by Nutritionlab, counts Hindustan Unilever and Fireside Ventures among its early backers. HUL and Fireside — holding 19.8% stake each — will exit with more than fourfold returns. Both invested in Wellbeing Nutrition about three years ago when the company was valued at about Rs 350 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8v4k2bP
via IFTTT

Read More

Trial by fire: Novelis may see bigger cash flow hit

In the wake of a second devastating fire at its Oswego facility, Novelis Inc. has revised its expectations dramatically, now forecasting a staggering impact on its free cash flow. Originally bracing for a loss of $550-650 million, the company is now looking at potential damages between $1.3-1.6 billion prior to insurance compensation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UL1XGcu
via IFTTT

Read More

Zydus Life cleared to sell life-saving cancer drug; SC tells Bristol Myers to map patents

The Supreme Court has provided Zydus Lifesciences with the go-ahead to launch its cancer drug biosimilar, countering efforts by Bristol Myers Squibb to halt its progress. The court has mandated that BMS verify how Zydus's product aligns with their patent claims, with options for BMS to request provisional support from the High Court following this analysis.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Az5Lho8
via IFTTT

Read More

Warburg-Mubadala leads race to buy majority in Soframycin maker

Exciting developments are afoot as Encube Ethicals, a key player in the pharma contract manufacturing sector, approaches a significant acquisition. The frontrunners, Warburg Pincus and Mubadala, are intensifying their bids, valuing the company at approximately ₹16,500 crore. This move underscores the burgeoning interest investors have in Indian CDMO companies, fueled by global supply chain shifts and evolving US policies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/x2Wz09B
via IFTTT

Read More

French pharma giant Servier to invest €15 million to launch global single-pill platform 'GATINN' in India

French pharma group Servier is expanding in India with a €15 million investment to launch GATINN, a global platform for single pill combinations (SPCs) targeting cardiometabolic and venous diseases. The India-based hub will coordinate research, manufacturing, and exports to international markets, aiming to improve patient adherence by combining multiple drugs into a single daily dose.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ePsq5ZK
via IFTTT

Read More

IHH Healthcare, Fortis launch initiative to strengthen healthcare innovation ecosystem

IHH Healthcare, in partnership with Fortis Healthcare, is proud to introduce IHH Catalyst. This groundbreaking initiative is designed to fast-track the integration of innovative technology in healthcare across India. By empowering promising health-tech and med-tech startups to shift from concept to concrete implementation, IHH Catalyst aims to elevate patient care and optimize hospital processes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KRwBh2b
via IFTTT

Read More

AstraZeneca gets CDSCO nod to market cancer drug Imfinzi for additional indication

AstraZeneca Pharma India has secured approval from India's drug regulator for Durvalumab, marketed as Imfinzi. This new indication allows its use in treating advanced or recurrent endometrial cancer. The drug will be administered in combination with other therapies for initial treatment. Following this, Durvalumab will be used as maintenance therapy for specific patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kXT7w6P
via IFTTT

Read More

Lupin clears Mirabegron patent dispute with Astellas in $90 million deal, secures US sales continuity

Drugmaker Lupin has settled a patent infringement dispute with Astellas Pharma over its Mirabegron product for $90 million. The agreement includes a $75 million prepaid option payment and a per-unit license fee. This resolution allows Lupin to continue marketing Mirabegron in the U.S., removing a significant legal obstacle.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TxGzH5g
via IFTTT

Read More

Decide on Piramal's Dahej plant in a week: Supreme Court to Gujarat Pollution Control Board

The Supreme Court has issued a swift order for the Gujarat Pollution Control Board to review Piramal Pharma's appeal to reactivate its Dahej manufacturing site, which was closed due to serious allegations related to hazardous waste management. The firm sought interim relief but was turned down by the court.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uUl4syC
via IFTTT

Read More

Sampre Nutrition arm to set up facility in Egypt

Sampre Nutrition will expand its global reach with a new manufacturing unit in Egypt. Orascom Industrial Parks has approved land for food processing and confectionery. This facility will boost production and support international growth. The company recently partnered with Reliance Consumer Products. Sampre Nutrition saw a significant revenue increase in the first half of the year.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Kn7VzqW
via IFTTT

Read More

Sun Pharma, Dr Reddy's & Lupin call for big push in drug innovation

Top Indian pharmaceutical leaders are urging a significant boost in research and development. They believe this focus on innovation is crucial for India to become a global biopharma manufacturing hub. Leaders from Sun Pharma, Cipla, Dr Reddy's Laboratories, and Lupin highlighted the need for greater investment and a shift towards developing novel drugs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qTCVJ6L
via IFTTT

Read More

India expected to see surge in Parkinson's disease, becoming 2nd-highest in 5 yrs: Experts at 6th International Annual Symposium-2026 in Kerala

India faces a surge in Parkinson's disease cases, potentially becoming second globally. Young-onset Parkinson's is a growing concern in Southeast Asia. Experts at a Kerala symposium highlighted the need for region-specific research and affordable treatments. Local manufacturing and international collaboration are key to expanding access to care for millions of patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ED1bohU
via IFTTT

Read More

Sun Pharma to stay disciplined on M&A, says Dilip Shanghvi

Sun Pharma plans a careful acquisition strategy. The company prioritizes organic growth to remain an attractive investment. Chairman Dilip Shanghvi highlighted a focus on innovative medicines in the US. Smaller acquisitions are being considered for emerging markets. The firm is also evaluating the biosimilar sector. This approach aims to strengthen long-term capabilities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/AgdF51Y
via IFTTT

Read More

Battle for cooking oil: Nutritionists reveal which oil is best and what separates one from another

The battle for cooking oil has been heating up — with everything from coconut, mustard and refined oils fighting for shelf space, while avocado oil puts in an appearance now. ET asks experts whether any one oil can ever triumph over others.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/06hLabo
via IFTTT

Read More

Strengthening the India-US medicines partnership important: IPA

The Indian Pharmaceutical Alliance welcomed an interim trade agreement between India and the US, emphasizing that medicine security is crucial for national security. The pact aims to boost bilateral trade by reducing import duties on various goods, including generics, and offers Indian MedTech exporters a competitive edge in the US market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Z7RWUdD
via IFTTT

Read More

Wipro seeks Schedule M exemption for Tumkur plant, regulator to review plea

Wipro has sought relaxation in requirement of Schedule M for specific categories like disinfectants. The product, Maxkleen, has been registered as a drug. The company has asked to allow them to manufacture the product without a drug licence.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VwMJ1gW
via IFTTT

Read More

Shukra Pharma gets YEIDA LoI for Rs 600-crore facility

Shukra Pharmaceuticals will establish a Rs 600-crore facility in Greater Noida. This plant will produce advanced surgical robotics and BNCT technology. The project aims to create over 900 direct jobs. A partnership with Borns Medical Robotics Inc. will bring surgical robotics to India. This venture seeks to make high-precision surgery affordable and accessible across India and Asia.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SphfEqT
via IFTTT

Read More

Alembic Pharmaceuticals gets USFDA nod for generic Parkinson's disease treatment tablets

Alembic Pharmaceuticals has secured a significant approval from the US health regulator. The company's generic version of Carbidopa, Levodopa, and Entacapone tablets, used for Parkinson's disease, has been cleared by the USFDA. This development marks a crucial step for Alembic in the US market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qLcCkGV
via IFTTT

Read More

Drug regulator steps up oversight on product changes after approval

Drug makers now need government approval for any quality changes to medicines. This applies to alterations affecting a drug's identity, strength, quality, purity, or potency. The regulator is strengthening manufacturing standards through risk-based audits and more inspections. This ensures only safe and effective medicines reach consumers. Manufacturers must inform the drug regulator about changes in manufacturing, packaging, or shelf life.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Zi7GST3
via IFTTT

Read More

Sun Pharma to pump in Rs 500 cr in Assam manufacturing unit

Sun Pharmaceutical will invest Rs 500 crore to establish a new manufacturing plant in Assam. This significant project will create over 500 direct employment opportunities. The company plans to implement the investment in two phases. Discussions covered land, water, power, and skilled manpower. Sun Pharmaceutical will focus on sustainable manufacturing practices.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dGMXqcE
via IFTTT

Read More

Biopharma Shakti: India targets China dependence, patent cliff

India is launching a major initiative to boost its biopharmaceutical manufacturing. This plan aims to reduce reliance on China for crucial drug components. It also seeks to capitalize on upcoming patent expirations of major global drugs. India will focus on becoming a hub for biosimilars and emerging biologics. This strategy will strengthen the nation's pharmaceutical industry on the global stage.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pRPewuC
via IFTTT

Read More

AstraZeneca gets CDSCO approval for Durvalumab in gastric cancer treatment

AstraZeneca Pharma India has secured approval for Durvalumab. This drug, combined with chemotherapy, will treat gastric and gastroesophageal junction cancer. The approval comes from the Central Drugs Standard Control Organisation. This new treatment offers a perioperative immunotherapy approach for adult patients. It aims to improve survival rates for those with resectable forms of the disease.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4xou9T2
via IFTTT

Read More

Medical gear firms told to 'promptly' flag adverse cases

Indian medical device firms must now promptly report all adverse events, both serious and non-serious, to the government's Materiovigilance Programme. This directive aims to boost patient safety and address concerns over underreporting of issues linked to locally manufactured equipment. Timely reporting is crucial for identifying risks and implementing necessary safety measures.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2hCVEeT
via IFTTT

Read More

US tariff cut to 18% to boost India’s medical device exports

India's medical device exports to the US will surge following a tariff cut. This move makes Indian products more competitive against China. Lower import duties will also benefit India's healthcare system by reducing costs for high-value equipment. Industry leaders hail the deal as transformative, unlocking significant market potential and fostering investment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TvIA4rh
via IFTTT

Read More

Budget relief on the label: Govt proposes to drop duty on rare disease drugs

The Indian budget proposes exempting seven rare disease drugs from import duties. This move aims to lower costs for expensive life-saving medicines. Patient groups welcome the relief for out-of-pocket expenses. However, some believe duty cuts alone will not make these drugs affordable for most Indians. The proposal also includes duty waivers on anti-cancer drugs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/g10ExeW
via IFTTT

Read More

Lupin rolls out generic oncology drug in US market

Drug firm Lupin has launched a generic cancer treatment medication in the US. The company introduced Dasatinib Tablets in various strengths. This product is bioequivalent to Sprycel Tablets. It is indicated for adults with Philadelphia chromosome-positive chronic myeloid leukemia. The US market for Dasatinib Tablets had significant sales.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WhdD0eY
via IFTTT

Read More

Budget 2026 gives biologics & biosimilars a major policy boost

India is set to become a global biopharmaceutical manufacturing hub. Finance Minister Nirmala Sitharaman announced a dedicated ₹10,000 crore program over five years. This initiative focuses on biosimilars and biologics, crucial for treating non-communicable diseases. The move aims to boost manufacturing, regulation, and clinical trials, positioning India for future global competition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/O5kjGqs
via IFTTT

Read More

Union Budget 2026: Govt to overhaul drug regulator CDSCO, announces Rs 10,000 crore ‘Biopharma Shakti’ push

India Budget 2026: India's drug regulatory authority, CDSCO, will be strengthened to meet global standards and speed up approvals. A new initiative, Biopharma Shakti, with a Rs 10,000 crore outlay over five years, will boost domestic production of biologics and biosimilars. This strategy includes establishing 1,000 accredited clinical trial sites and upgrading NIPERs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Sfmg2YO
via IFTTT

Read More

Budget 2026: Sitharaman launches 'Biopharma Shakti' with a Rs 10,000-crore bet to heal India, power manufacturing

Union Budget 2026: With the announcement of the 'Biopharma Shakti' initiative, India is gearing up to take the world stage in biopharmaceutical manufacturing. Finance Minister Nirmala Sitharaman revealed plans to inject Rs 10,000 crore into this sector over the next five years. This initiative will significantly enhance domestic production of biologics and biosimilars.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PVWtc6x
via IFTTT

Read More

Sun Pharmaceutical to adopt a 'disciplined' approach to M&A: Dilip Shanghvi

Asked about the strategic priorities in the US, he added: "Not only the US, but we have interest in selling innovative medicines globally... for emerging markets we are looking at tuck-ins or smaller acquisitions which we can look at integrating with our existing business to get scale in the emerging markets." Shanghvi added.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/g2ykR0J
via IFTTT

Read More

Indoco Remedies gets USFDA nod to sell generic epilepsy medicine

Indoco Remedies has secured approval from the US health regulator for its generic Lacosamide oral solution. This medication is used to treat epilepsy in adults and children. The approval allows Indoco Remedies to market the drug, which is a generic version of Vimpat Oral Solution. Manufacturing will take place at their Goa facility.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xR0Qwr2
via IFTTT

Read More

Bristol Myers moves SC to stop Zydus from selling biosimilar cancer drug

US firm Bristol Myers Squibb is in the Supreme Court seeking to halt Zydus Lifesciences from manufacturing and selling a biosimilar cancer drug. The court will hear the appeal on February 4. BMS markets the drug nivolumab under brands Opdivo and Opdyta.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/muyts60
via IFTTT

Read More

Minimum import price set for Penicillin G, salts

The Indian government has imposed a minimum import price on crucial pharmaceutical ingredients like penicillin G, amoxicillin, and 6-APA. This move aims to counter cheap imports from China and support domestic producers. The price restrictions will be in effect for one year. This measure applies to imports for domestic consumption, ensuring a level playing field for local manufacturers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/z8r9UQt
via IFTTT

Read More

Eco Survey: Pharma focus turns to value, innovation over volumes

India's pharma sector is moving towards high-value products like complex generics and biosimilars. The medical devices industry is also growing, with exports reaching new heights. Advanced manufacturing technologies are key to this expansion. India is a major global supplier of vaccines and is increasingly producing sophisticated medical equipment. This marks a significant step in high-tech medical manufacturing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/AVgdDvf
via IFTTT

Read More

Reliance, Capri Global to acquire Mumbai’s SevenHills Hospital

Reliance Industries and Capri Global will acquire Mumbai’s 1,500-bed SevenHills Hospital, ending an eight-year impasse. The hospital will be converted into a not-for-profit entity, with funds infused via equity support.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jyVMDnm
via IFTTT

Read More

Drug misuse: Govt may curb 'Pregabalin' sales

The government is looking to control the sale of Pregabalin. This common medicine is being misused. The government wants to make sure it is only sold with a doctor's prescription. This move follows concerns raised by authorities. Pregabalin is used for pain and seizures. Stricter rules are being considered to prevent its misuse.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eR6UohJ
via IFTTT

Read More

S&P Global upgrades Biocon Biologics credit rating To 'BB+'

Biocon Biologics has received a credit rating upgrade from S&P Global Ratings. The company's long-term issuer credit rating is now 'BB+' with a stable outlook. This upgrade follows Biocon's simplification of its capital structure and reduction of debt. New product launches and industry trends are expected to support Biocon's earnings growth in the coming years.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EBvlO6z
via IFTTT

Read More

India-EU trade deal: A tonic for pharma companies

India and the EU are set to eliminate tariffs on pharmaceutical products, a move expected to significantly benefit India's pharma industry by reducing input costs and improving access to advanced medicines. Experts believe this will enhance trade and collaboration, strengthening India's position in the EU market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HQSgTiI
via IFTTT

Read More

India's over-the-counter drugs market to hit Rs 98,000 crore by 2030: Report

An EY report estimated that India's OTC market, valued around Rs 47,000 crore in 2024, is projected to grow to Rs 98,000 crore around 13 per cent CAGR through 2030.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cAKW5PH
via IFTTT

Read More

India-EU FTA to strengthen position of Indian formulations, medicines in EU

A new India-EU free trade agreement promises to boost Indian pharmaceutical exports. Lower tariffs will make Indian medicines more competitive in Europe. This deal also aims to improve access to affordable, high-quality medicines for Indian patients. Experts anticipate significant price reductions for advanced therapies in the coming years. The agreement strengthens trade and collaboration between the two regions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MNICFpz
via IFTTT

Read More

PRISM-PCI Conclave 2026 in Vapi highlights India’s evolving approach to heart care

The PRISM-PCI Conclave 2026 highlighted India's significant advancements in cardiac care, showcasing its evolution from a consumer to a contributor in medical technology innovation. The event emphasized precision-driven strategies and the growing role of home-grown technologies in addressing complex cardiovascular diseases, improving patient outcomes globally.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/noeyFjI
via IFTTT

Read More

Cipla plans deeper push in domestic market and chronic therapies over next 2–3 years

Cipla's incoming MD and CEO-designate, Achin Gupta, outlined a two-to-three-year strategy focusing on deepening the domestic market presence and pursuing selective inorganic growth and innovation. The company aims to strengthen its respiratory leadership and achieve similar dominance in cardiometabolic diseases and obesity, with a near-term focus on the GLP-1 weight-loss segment through its partnership with Eli Lilly.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0Zv75Wb
via IFTTT

Read More

China halts sale of Sun Pharma drug used to treat dementia

China's medicine regulator has halted the import, sale, and use of Sun Pharmaceutical Industries' dementia drug, rivastigmine hydrogen tartrate capsules. A recent inspection revealed production process shortcomings, including contamination prevention and quality management issues. This follows a 2024 warning letter from the U.S. FDA regarding similar manufacturing practice violations at the same Indian site.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TwltGCH
via IFTTT

Read More

India’s 'Healthcare Budget' crossroads: Why the next leap is about design, not just spend

Union Budget 2026: India's healthcare system faces a structural shift from episodic care to lifelong management of chronic diseases. The Union Budget must move beyond incremental spending to architect a resilient system by addressing hospital capacity, insurance viability, human capital development, and digital health integration. A multi-year roadmap is crucial for long-term growth.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/OsWbIHA
via IFTTT

Read More

Sun Pharma, Cipla recall products in US over manufacturing issues: USFDA

Sun Pharma and Cipla, two leading drug manufacturers from India, are taking precautionary measures by recalling products in the United States due to safety concerns. Sun Pharma's recall involves their generic skin condition treatments, identified to have impurity problems, while Cipla is addressing contamination in an injection linked to particulate matter. These recalls align with the oversight of the U.S.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dumaP6g
via IFTTT

Read More

Pitiless Cut: Blood money for a broken hip

India's Supreme Court has ordered Johnson & Johnson to pay more compensation for faulty hip implants. This decision comes after a long legal battle for justice for patients. The court's ruling fixes culpability on the global company. However, the compensation awarded to Indian patients is significantly less than what was given in the US. Many patients continue to seek relief.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/80I5azy
via IFTTT

Read More

Sun Pharma gets DCGI nod to launch generic semaglutide for weight management

Sun Pharma has gained the green light from the DCGI for its much-anticipated generic version of semaglutide injection, targeting chronic weight management under the name Noveltreat. With Novo Nordisk's patent expiration on the horizon, this initiative marks a pivotal moment in accessible healthcare.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9YVxW2L
via IFTTT

Read More

Sun Pharma gets DCGI nod for Wegovy-like weight loss drug, launch after Novo Nordisk's patent expiry

Sun Pharma has received DCGI approval to launch Noveltreat, a generic semaglutide injection for chronic weight management in India. This GLP-1 receptor agonist will be available after patent expiry, offering a crucial treatment option for India's growing obesity and diabetes burden. The approval follows successful Indian clinical trials.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ijY5MyZ
via IFTTT

Read More

New drugs could reach market sooner as govt halves trial review timeline

The Indian government is shaking up the pharmaceutical sector by slashing the review period for manufacturing applications for new drugs to 45 days. Now, manufacturers can initiate clinical trials or bioequivalence studies with just a prior notification to the regulators, ditching the old requirement for express permission.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Np3P9nl
via IFTTT

Read More

Bastar's first super-specialty hospital opens

Bastar region will soon have its first super specialty hospital. Located in Jagdalpur, the facility opens in February. Hyderabad-based Continental Hospitals partners with the Chhattisgarh government. This 240-bedded hospital will offer advanced medical services.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4FoeWz6
via IFTTT

Read More

Budget 2026: Industry leaders seek funding framework for innovation, R&D in pharma, MedTech

Industry leaders are calling for a structured funding framework in the upcoming Union Budget. This aims to boost innovation and R&D in India's pharmaceutical and MedTech sectors. The goal is to drive advanced research and achieve the Viksit Bharat vision. Companies seek support for complex therapies and improved patient access.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GsVdtYK
via IFTTT

Read More

Zydus launches biosimilar for treatment of multiple cancers

Zydus Lifesciences has launched Tishtha, the world's first biosimilar of Nivolumab, in India. This drug treats multiple cancers. Tishtha will be available in 100 mg and 40 mg dosages. The prices are significantly lower than the reference drug. This launch expands access to immuno-oncology therapies. The company aims to support patients with consistent care.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mgIh9iF
via IFTTT

Read More

Over 160 drug samples found sub-standard in December

A recent inspection by India's drug regulator has revealed a troubling statistic: 167 medication samples were classified as not of standard quality (NSQ) in December, with valuable insights from both central and state laboratories aiding the findings. Many of these samples consisted of widely used drugs, highlighting a critical need for heightened quality control.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5euzjas
via IFTTT

Read More

CDSCO finds over 160 drug samples as 'not of standard quality' for December

In December 2025, 74 drug samples were identified as Not of Standard Quality (NSQ) by Central Drugs Laboratories and 93 by State Drugs Testing Laboratories. Additionally, seven spurious drug samples were identified across various zones, manufactured by unauthorized entities. These findings are part of routine regulatory surveillance to ensure market safety.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pmvjSGU
via IFTTT

Read More

Drug maker Lupin inks licensing pact with Galenicum for injectable Semaglutide

Drug maker Lupin announced a significant partnership. Its subsidiary, Lupin Atlantis Holdings SA, has signed an agreement with Galenicum Health. This collaboration focuses on diabetes and weight management medication, specifically injectable Semaglutide. Galenicum will handle development and manufacturing. Lupin will manage regulatory submissions, approvals, and commercialisation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Z3k2BLK
via IFTTT

Read More

Delhi High Court denies interim protection to Alkem in 'A to Z' trademark case

The Delhi High Court has denied Alkem Laboratories interim protection in a trademark dispute. Prevego Healthcare & Research can continue selling its multivitamin product under the brand name Multivein AZ. Alkem Laboratories had claimed infringement of its A to Z and A to Z-NS trademarks. The court noted differences in fonts, color schemes, and trade dress.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RI5e2nz
via IFTTT

Read More

Novo Holdings buys 49% stake in Surya Hospitals

Novo Holdings, a major investment firm, has acquired a 49% stake in Surya Hospitals for an estimated Rs 1,000-1,200 crore. This strategic move highlights Novo Holdings' focus on specialized healthcare in India, particularly in women's and children's care, where Surya Hospitals has a strong reputation. The deal underscores the ongoing investment trend in the Indian hospital sector.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CTcglWU
via IFTTT

Read More

Sun Pharma places non-binding offer for US-based Organon in its boldest global bet ever

Sun Pharmaceutical Industries Ltd has submitted a non-binding offer to acquire US-based Organon for an all-cash deal, securing $10-14 billion in acquisition financing. This move marks Sun Pharma's boldest global bet, aiming to bolster its presence in women's health biopharma and biosimilars. The acquisition, if successful, would be the largest by an Indian pharmaceutical company.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KSMml42
via IFTTT

Read More

Syngene expands research collaboration with Bristol Myers Squibb

Syngene International has extended its research partnership with Bristol Myers Squibb until 2035. This expanded agreement covers more services for drug development, from discovery to manufacturing. The collaboration, which began in 1998, will now focus on building new capabilities for future programs. This move aims to accelerate the delivery of new medicines to patients worldwide.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bXsF7u0
via IFTTT

Read More

Sun Pharma clarifies $10 bn Organon acquisition report, calls it 'speculative in nature'

Sun Pharma has addressed speculation regarding a potential $10 billion acquisition of US firm Organon. The Indian drugmaker stated the reports are speculative and no material event requires disclosure. Sun Pharma adheres to high governance standards. Organon, focused on women's health and biosimilars, was spun off from Merck in 2021.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PHUv1mE
via IFTTT

Read More

Sun Pharma looks to rise in US with $10 billion Organon buy

India's largest drugmaker, Sun Pharma, is considering a major acquisition. The company is evaluating the purchase of US-based Organon, a specialist in women's health. This potential deal is valued at around $10 billion. A successful acquisition would be a significant move for Sun Pharma, strengthening its presence in the US market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0h8sbam
via IFTTT

Read More

Brazil, Nigeria emerging as key export destinations for Indian pharmaceuticals

Indian pharmaceutical exports are seeing strong growth. Brazil and Nigeria are now important markets for Indian medicines. This shows a wider reach for Indian pharma products. The US remains the biggest buyer. Other countries like France and Germany are also increasing their purchases. This diversification strengthens India's position as a global medicine supplier.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/YkUXJmF
via IFTTT

Read More

PE backed ASG Eye hires Morgan Stanley and three other bankers for upcoming IPO

ASG Hospital, a major eye care chain, is preparing for its initial public offering. The company has selected four investment banks to manage the process. ASG plans to raise between ₹3,000 and ₹4,000 crore. This offering is expected to take place in the financial year 2027. The move follows strong market interest in the healthcare sector.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lFGetrH
via IFTTT

Read More

IHCL to aquire 51% stake in Brij Hospitality

Indian Hotels Company, backed by Tata Group, is acquiring a majority stake in Brij Hospitality. This move aims to bolster IHCL's presence in the boutique luxury hotel market. The deal, valued at up to Rs 225 crore, will integrate Brij's portfolio of 22 hotels. This acquisition is expected to be completed by March 2026.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vZXRDUS
via IFTTT

Read More

Zydus Lifesciences gets USFDA nod for generic blood disorder drug

Zydus Lifesciences has secured final approval from the USFDA for its generic Eltrombopag tablets. These tablets treat low platelet counts in specific blood disorders. The approval covers multiple strengths. Production will occur at the company's Ahmedabad facility. This development marks a significant step for Zydus in the US market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rdIUcPe
via IFTTT

Read More

Delhi HC restores ban on 2 diabetes FDCs

The Delhi High Court has made waves with its recent judgment, reinstating a ban on two fixed-dose combination drugs for managing Type II Diabetes Mellitus, significantly affecting leading pharmaceutical corporations. The ruling reaffirmed the government's power to eliminate drugs deemed risky to health.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aSpsy7h
via IFTTT

Read More

Dr Reddy's launches generic OTC ophthalmic solution in US market

Dr Reddy's Laboratories has launched a new eye drop in the United States. This over-the-counter solution treats itchy eyes. It is an antihistamine eye drop. The company received approval from the US Food and Drug Administration. This launch expands their existing eye care products. It highlights their ability to bring store-brand equivalents to the US market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ckLF6r3
via IFTTT

Read More

Indian hospital chain Narayana Health eyes international expansion

Narayana Hrudayalaya is gearing up to make its mark in Western healthcare markets. Leveraging its innovative, affordable healthcare model that has thrived in India, the company is now setting its sights on the UK as a strategic launchpad for further global expansion.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ghdU8Wf
via IFTTT

Read More

Apollo Hospitals demerger is a biz call taken for shareholders, says Suneeta Reddy; rules out family rift

Apollo Hospitals MD Suneeta Reddy says the group’s restructuring is about business strategy, not family dynamics, aiming to unlock value by separating hospital and pharmacy-digital units. She stresses close ties with sister Shobana Kamineni, outlines expansion in metros and Tier-II cities, focus on preventive care, tech-led growth, and mentoring the next generation of leaders.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KyNFkbC
via IFTTT

Read More

Biocon arm gets USFDA nod for generic Everolimus tablets

Biocon's arm, Biocon Pharma Ltd, has secured USFDA approval for its generic Everolimus tablets. This medication aids in treating tuberous sclerosis complex, a rare genetic disorder causing tumors. The approval for 2mg, 3mg, and 5mg strengths bolsters Biocon's drug offerings, providing a new treatment option for adult and pediatric patients with specific TSC-related conditions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fRySVtg
via IFTTT

Read More

Alembic Pharmaceuticals gets USFDA tentative nod for generic cancer treatment drug

Alembic Pharmaceuticals has secured tentative approval from the USFDA for its Bosutinib tablets. These tablets are used to treat certain types of cancer, specifically chronic myelogenous leukemia. The approval covers the 400 mg strength. This development marks a significant step for Alembic in the US market. The company previously received final approval for other strengths of the same drug.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rH46BXY
via IFTTT

Read More

Delhi HC clears Zydus to sell biosimilar of BMS cancer drug Nivolumab

The Delhi High Court has permitted Zydus Lifesciences to produce and market a biosimilar cancer drug. This decision comes as the patent for the original drug, Nivolumab, nears its expiration. The court prioritized patient access to affordable treatment. Zydus can now proceed with its biosimilar, ZRC-3276, while maintaining sales records.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1xJoX3t
via IFTTT

Read More

Budget 2026: Pharma, med-tech companies seek PLI extension to cover APIs

The industry expects the government to address these issues in the Union budget announcement this year. Sudarshan Jain, secretary general of Indian Pharmaceutical Alliance (IPA) said the recent global challenges like US tariffs, supply chain disruptions and geopolitical uncertainty have underscored the need for strategic support, and hence, restoring 200% weighted deduction for research and development expenditures would be a significant step.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/OqjgdAW
via IFTTT

Read More

Aurobindo Pharma’s Dyrupeg faces Health Canada compliance notice

CuraTeQ Biologics, a part of Aurobindo Pharma, has secured a crucial approval from Health Canada for its biosimilar drug Dyrupeg. This medication helps cancer patients with low neutrophil counts. The approval confirms Dyrupeg's high similarity to an existing reference biologic drug. Earlier, Dyrupeg also gained marketing authorization in the European Union and the UK.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xyQkAH5
via IFTTT

Read More

Canadian pharmacy platform to offer India-sourced Ozempic to US patients

SaveRxCanada.to, an online pharmacy platform, announced it is now offering Ozempic sourced from India to U.S. patients at significantly lower prices than U.S. retail pharmacies. The company claims to connect patients with licensed international pharmacies, though Novo Nordisk denies any relationship with the platform.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/297GfUX
via IFTTT

Read More

Cardiac drugs log highest sales in 2025 as NCD cases surge

Heart medicines led sales in 2025, a trend set to continue. Respiratory and anti-diabetes drugs followed. Cardiac drug sales grew 13%, with similar strong performance expected. Rising non-communicable diseases like hypertension fuel this growth. Increased awareness and longer treatment durations contribute.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mNpRfx4
via IFTTT

Read More

Ayushman Bharat: UP cuts claim pendency sharply, speeds up hospital payments

Uttar Pradesh is making waves in healthcare with significant advancements in settling Ayushman Yojana claims. The state is firmly committed to timely reimbursements for partner hospitals, leading to a culture of transparency in claims processing. These initiatives have slashed the backlog of pending claims, ensuring that hospitals provide swift treatment to Ayushman card holders.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0WOf5sY
via IFTTT

Read More

Granules India gets USFDA tentative nod for generic ADHD treatment tablets

Granules Pharmaceuticals, Inc., a subsidiary of Granules India, has achieved a significant milestone with the tentative green light from US health authorities for its generic amphetamine extended-release tablets, designed for managing attention deficit hyperactivity disorder.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/naEeM6W
via IFTTT

Read More

Future diabetes care seen leaning towards GLP-1 drugs

The diabetes treatment landscape in India is on the brink of transformation. Innovative GLP-1 medications are set to redefine therapy standards, providing remarkable advantages in glucose regulation and weight management, while also safeguarding vital organs such as the heart and kidneys.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/x9NhIZo
via IFTTT

Read More

Budget 2026: Volume to value - How India can get a quiet superpower

India Budget: India's pharmaceutical industry, a global leader in volume, is poised to leverage its scale for greater international influence. The upcoming Union Budget 2026-27 presents a crucial opportunity to shift focus from low-margin generics to high-value segments like biologics and novel drug discovery.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/OEbw4tn
via IFTTT

Read More

HC seeks Novo Nordisk's reply on Natco plea to revoke patent

The Delhi High Court has asked Novo Nordisk to explain why its patent for the diabetes and weight loss drug semaglutide should not be cancelled. Natco Pharma filed the petition. Novo Nordisk's patent expires in March. This has sparked patent disputes as other companies aim to produce their own versions of the drug.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WFIrpbg
via IFTTT

Read More

Biocon Biologics to introduce three new biosimilars for cancer treatment

Biocon Biologics will launch three new oncology biosimilars. These include Trastuzumab/Hyaluronidase, Nivolumab, and Pembrolizumab. The company aims to expand access to vital cancer treatments. These biosimilars will offer cost-effective alternatives. Biocon Biologics will have one of the most comprehensive oncology portfolios. This move strengthens its commitment to patient care.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/f9msa6p
via IFTTT

Read More

Max Healthcare partners with The Learning Lab for advance healthcare capacity building, research

Max Healthcare has partnered with UK-based The Learning Lab to advance healthcare capacity-building and foster joint research. The collaboration will co-create training modules for healthcare professionals, aiming to strengthen clinical competencies and improve patient outcomes. This initiative combines Max Healthcare's clinical experience with The Learning Lab's educational expertise to deliver practical, evidence-based learning.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uA3vO4L
via IFTTT

Read More

IIT Roorkee hosts 'AHEAD 2025' global health conference

IIT Roorkee hosted the "AHEAD 2025" International Conference on Health and Development, bringing together global experts to address critical challenges. The event focused on policy-relevant research for health systems resilience, climate health, and demographic change, aligning with India's development agenda and SDGs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BZXKoE6
via IFTTT

Read More

Indian fertility experts advise caution on clinical use of new 'Non-Invasive' Embryo Genetic Test

Leading Indian fertility experts have cautioned against using non-invasive embryo genetic testing (niPGT) for routine clinical decisions. A joint review by ISAR, IFS, and ACE found the technique prone to high misdiagnosis rates, potentially leading to incorrect embryo selection or discarding. The technology, while promising, lacks sufficient evidence for clinical use.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Y58haKj
via IFTTT

Read More

Budget for 'pharmacy of the world': What Sitharaman & Co can do to make medicines more affordable in India

Union Budget 2026: India's pharmaceutical landscape is on the brink of a transformative boom. To maintain this upward trajectory, the focus must shift towards fostering innovation and enhancing the efficiency of drug manufacturing. Strategic government funding is essential to bolster research initiatives, support production facilities, and strengthen healthcare frameworks.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fv9FTCQ
via IFTTT

Read More